Evidence map›Paper›PMID 31262571›Full record

ArticleClinics and research in hepatology and gastroenterology2020

Gut microbiota in PSC : From association to possible causality. Commentary to "Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis" by Nakamoto et al., Nature Microbiology, January 2019.

Sara Lemoinne, Joao Sabino, Harry Sokol

Abstract readComment
PubMed Publisher
In one paragraph

Article in Clinics and research in hepatology and gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Sara LemoinneDivision of Liver Diseases, Icahn Medical school at Mount Sinai, New York, NY, USA; Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Hôpital Saint Antoine, Service d'Hépatologie, 75012 Paris, France. Electronic address: sara_lemoinne@yahoo.fr.
Joao SabinoThe Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Gastroenterology, University Hospitals of Leuven, Leuven, Belgium.
Harry SokolSorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Hôpital Saint Antoine, Service de Gastroenterologie, 75012 Paris, France; INRA, UMR1319 Micalis, AgroParisTech, Jouy-en-Josas, France.
Inserm · FRMount Sinai Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary sclerosing cholangitis is a chronic cholestatic liver disease, whose pathogenesis remains poorly understood. Several studies have shown that PSC patients harbor an impaired gut microbiota. A recent study confirmed that PSC patients displayed a bacterial dysbiosis, characterized by an increased abundance of three different bacteria: Klebsiella pneumoniae, Proteus mirabilis and Enterococcus gallinarum. This study also provides evidence for a possible mechanism of action of these bacteria: notably the formation of pores in gut epithelium leading to an increased gut permeability and the induction of liver inflammation characterized by an increased proportion of T helper 17 (T

Indexed as

Cholangitis, SclerosingGastrointestinal MicrobiomeEnterococcusHumansLiverTh17 CellsGut microbiotaPrimary sclerosing cholangitisTH17 cells

Identifiers

PMID31262571
OpenAlexW2954129728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.